Drugs and Devices

Single-dose IV Zofran pulled from market

On Dec. 4, the U.S. Food and Drug Administration announced that the 32 mg, single IV dose of the anti-nausea drug Zofran (ondansetron hydrochloride) will no longer be marketed. The dose has been associated with prolonged QT interval, which can lead to Torsades de Pointes, which can be fatal. Read more.


Related Articles:

Leave a Reply

You have to agree to the comment policy.

 

Shares